ASCO® GI 2024: GoldenBiotech’s Phase 2 Metastatic Pancreatic Cancer Study Selected for Poster Presentation and Discussion (Abstract # 648. Poster Bd. # K17)

TAIPEI, Nov. 10, 2023-- Golden Biotechnology Corp. (TPEX 4132) ("GoldenBiotech", GBC), an advanced biopharmaceutical drug development company, is pleased to announce that ASCO® Gastrointestinal Cancers Symposium 2024 Committee has selected GBC’s Phase 2 Study entitled “A Phase I/II study of Antroquinonol in combination with Nab-Paclitaxel and Gemcitabine for patients with metastatic pancreatic cancer” for a Poster Presentation and discussion.

The 2024 ASCO® GI Cancers Symposium offers the latest innovative science, solution-focused strategies, and multidisciplinary approaches in GI cancer treatment, research, and care. ASCO® GI Cancers Symposium will be held on January 18-20, 2024 at Moscone West, San Francisco, CA and online.